| Literature DB >> 32849329 |
Thrimendra Kaushika Dissanayake1, Sascha Schäuble2, Mohammad Hassan Mirhakkak2, Wai-Lan Wu1, Anthony Chin-Ki Ng1, Cyril C Y Yip1, Albert García López2, Thomas Wolf2, Man-Lung Yeung1,3,4,5, Kwok-Hung Chan1, Kwok-Yung Yuen1,3,4,5, Gianni Panagiotou2,6, Kelvin Kai-Wang To1,3,4,5.
Abstract
Rhinovirus (RV) and influenza virus are the most frequently detected respiratory viruses among adult patients with community acquired pneumonia. Previous clinical studies have identified major differences in the clinical presentations and inflammatory or immune response during these infections. A systematic transcriptomic analysis directly comparing influenza and RV is lacking. Here, we sought to compare the transcriptomic response to these viral infections. Human airway epithelial Calu-3 cells were infected with contemporary clinical isolates of RV, influenza A virus (IAV), or influenza B virus (IBV). Host gene expression was determined using RNA-seq. Differentially expressed genes (DEGs) with respect to mock-infected cells were identified using the overlapping gene-set of four different statistical models. Transcriptomic analysis showed that RV-infected cells have a more blunted host response with fewer DEGs than IAV or IBV-infected cells. IFNL1 and CXCL10 were among the most upregulated DEGs during RV, IAV, and IBV infection. Other DEGs that were highly expressed for all 3 viruses were mainly genes related to type I or type III interferons (RSAD2, IDO1) and chemokines (CXCL11). Notably, ICAM5, a known receptor for enterovirus D68, was highly expressed during RV infection only. Gene Set Enrichment Analysis (GSEA) confirmed that pathways associated with interferon response, innate immunity, or regulation of inflammatory response, were most perturbed for all three viruses. Network analysis showed that steroid-related pathways were enriched. Taken together, our data using contemporary virus strains suggests that genes related to interferon and chemokine predominated the host response associated with RV, IAV, and IBV infection. Several highly expressed genes, especially ICAM5 which is preferentially-induced during RV infection, deserve further investigation.Entities:
Keywords: ICAM5; cytokines; influenza; interferons; rhinovirus; transcriptomics analysis
Year: 2020 PMID: 32849329 PMCID: PMC7396524 DOI: 10.3389/fmicb.2020.01580
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Infection of influenza A virus (IAV), influenza B virus (IBV) or rhinovirus (RV) in Calu-3 cells. (A) Calu-3 cells were infected with IAV, IBV, or RV at 1 MOI. IAV, IBV, and RV antigen expression was determined at 24 h post infection. Antigen expression was determined using fluorescein-tagged murine monoclonal antibodies against IAV, IBV, or RV. Mock-infected cells stained with respective monoclonal antibodies against IAV, IBV, or RV are shown in the bottom row. White scale bar = 50 μm. (B) Multicycle growth assay. Calu-3 cells were infected with IAV, IBV, or RV at 1 MOI. Viral load was determined using real-time RT-qPCR. (C) Cytokine and chemokine expression of Calu-3 cells infected with IAV, IBV, or RV at 1 MOI. Cytokine expression was determined using real time RT-PCR. GAPDH was used for normalization of gene expression. (D) Cytokine and chemokine protein expression of Calu-3 cells infected with IAV, IBV, or RV at 1 MOI. Protein expression was determined using ELISA. Bars (B,C) represent means (error bars show standard error of mean) of duplicates in two independent experiments. Bars (D) represent means (error bars show standard error of mean) of triplicates in one independent experiment. Statistical significance (for B–D) was calculated with two-way ANOVA. (∗P< 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ****P < 0.0001). hpi, hours post infection; MOI, multiplicity of infection.
FIGURE 2Hierarchical clustering of gene expression for (A) 12 hpi time point and (B) 24 hpi time point showing a distinct gene expression for IAV, IBV, and RV. (C) Principal component analysis for 6, 12, and 24 hpi.
Top 20 upregulated DEGs when compared with mock-infected cells.
| IAV vs. mock | IBV vs. mock | RV vs. mock | ||||
| Hours post-infection | Gene name | log2 (Fold Change) | Gene name | log2 (Fold Change) | Gene name | log2 (Fold Change) |
| 12 | 7.10 | 9.88 | 7.61 | |||
| 7.09 | 9.63 | 7.38 | ||||
| 6.89 | 9.55 | 7.34 | ||||
| 6.76 | 9.36 | 7.14 | ||||
| 6.68 | 8.95 | 6.13 | ||||
| 6.44 | 8.91 | 6.01 | ||||
| 6.28 | 8.59 | 5.77 | ||||
| 6.19 | 8.40 | 5.51 | ||||
| 5.92 | 8.14 | 5.38 | ||||
| 5.86 | 8.09 | 5.36 | ||||
| 5.76 | 8.01 | 5.25 | ||||
| 5.58 | 7.89 | 5.12 | ||||
| 5.53 | 7.70 | 5.02 | ||||
| 5.53 | 7.42 | 4.65 | ||||
| 5.52 | 7.33 | 4.63 | ||||
| 5.52 | 7.24 | 4.61 | ||||
| 5.43 | 7.18 | 4.48 | ||||
| 5.40 | 7.10 | 4.46 | ||||
| 5.40 | 6.99 | 4.35 | ||||
| 5.39 | 6.94 | 4.31 | ||||
| 24 | 10.32 | 12.08 | 8.90 | |||
| 9.20 | 11.58 | 7.68 | ||||
| 9.01 | 10.44 | 7.62 | ||||
| 8.56 | 10.35 | 7.59 | ||||
| 8.31 | 10.21 | 7.45 | ||||
| 8.26 | 10.07 | 7.21 | ||||
| 8.21 | 9.90 | 7.13 | ||||
| 8.11 | 8.97 | 6.92 | ||||
| 7.98 | 8.79 | 6.90 | ||||
| 7.76 | 8.76 | 6.89 | ||||
| 7.69 | 8.73 | 6.79 | ||||
| 7.64 | 8.41 | 6.77 | ||||
| 7.55 | 8.33 | 6.71 | ||||
| 7.48 | 8.28 | 6.53 | ||||
| 7.27 | 8.12 | 6.47 | ||||
| 7.21 | 8.04 | 6.09 | ||||
| 7.13 | 7.84 | 6.01 | ||||
| 7.01 | 7.83 | 5.82 | ||||
| 6.94 | 7.82 | 5.82 | ||||
| 6.82 | 7.71 | 5.77 | ||||
FIGURE 3(A) Heatmap for top-20 differentially expressed genes with an absolute log2 fold change ≥ 2 across all virus infections with significant infection annotated. (B) ICAM5 expression. Monoplex ICAM5 specific real time RT-PCR was performed for IAV, IBV, and RV-infected cells. **P < 0.01; ***P <0.001.
Top 10 reactome pathways that enriched for IAV, IBV, or RV infection when compared with mock infection at 12 hpi using g:Profiler analysis.
| IAV | IBV | RV | |||||||
| Reactome pathway | FDR-adjusted | Enrichment score | Reactome pathway | FDR-adjusted p-value | Enrichment score | Reactome pathway | FDR-adjusted | Enrichment score | |
| 1 | Interferon signaling | 2.1E-27 | 26.69 | Cell cycle | 1.4E-20 | 19.86 | Interferon signaling | 4.0E-25 | 24.39 |
| 2 | Cytokine signaling in immune system | 4.1E-27 | 26.38 | Influenza infection | 1.7E-20 | 19.78 | Interferon alpha/beta signaling | 2.5E-22 | 21.60 |
| 3 | Interferon alpha/beta signaling | 1.3E-24 | 23.90 | L13a-mediated translational silencing of ceruloplasmin expression | 2.6E-20 | 19.58 | Cytokine signaling in immune system | 1.2E-17 | 16.92 |
| 4 | Immune system | 2.3E-21 | 20.64 | Cytokine signaling in immune system | 3.4E-20 | 19.47 | Interferon gamma signaling | 8.4E-13 | 12.08 |
| 5 | Eukaryotic translation elongation | 7.4E-20 | 19.13 | Cap-dependent translation initiation | 4.4E-20 | 19.35 | Immune system | 1.9E-08 | 7.72 |
| 6 | Peptide chain elongation | 7.4E-20 | 19.13 | Eukaryotic translation initiation | 4.4E-20 | 19.35 | Interleukin-4 and Interleukin-13 signaling | 6.1E-07 | 6.21 |
| 7 | Viral mRNA translation | 7.4E-20 | 19.13 | Influenza life cycle | 6.5E-20 | 19.18 | Interleukin-10 signaling | 8.5E-06 | 5.07 |
| 8 | Nonsense mediated decay (NMD) enhanced by EJC | 1.4E-19 | 18.85 | Signaling by ROBO receptors | 8.8E-20 | 19.06 | Antiviral mechanism by IFN-stimulated genes | 2.0E-05 | 4.70 |
| 9 | Nonsense-mediated decay (NMD) | 1.4E-19 | 18.85 | Cell cycle. Mitotic | 1.1E-19 | 18.95 | FOXO-mediated transcription | 9.4E-05 | 4.03 |
| 10 | Influenza infection | 1.6E-19 | 18.79 | GTP hydrolysis and joining of the 60S ribosomal subunit | 1.8E-19 | 18.74 | Signaling by interleukins | 1.5E-04 | 3.82 |
FIGURE 4Heatmap for differentially expressed genes with an absolute log2 fold change ≥ 2 across all virus infections. Three subclusters as determined by hierarchical clustering are shown and GSEA was performed for each individual sub-cluster and the major significantly enriched pathways are indicated.
FIGURE 5Network visualization of GSEA derived categories related to steroid biosynthesis. Red: up-regulated, Blue: down-regulated; Size: log2 fold change. Green edges: gene is shared among all categories; magenta: genes are only shared among response to corticosteroid and response to glucocorticoid categories.